omeprazole has been researched along with Esophagitis in 177 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Esophagitis: INFLAMMATION, acute or chronic, of the ESOPHAGUS caused by BACTERIA, chemicals, or TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 9.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 9.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| " The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis." | 9.12 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. ( Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M, 2006) |
| "Gastro-oesophageal reflux disease patients (349) with endoscopically documented healed erosive oesophagitis (grade 0 or 1) were randomly assigned to receive pantoprazole (10, 20 or 40 mg/q." | 9.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| "To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients." | 9.11 | Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. ( Chiu, YL; Kovacs, TO; Lee, CQ; Metz, DC; Pilmer, BL, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 9.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis." | 9.10 | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. ( Bochenek, WJ; Metz, DC, 2003) |
| "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age." | 9.10 | Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002) |
| "To evaluate the efficacy and tolerability of rabeprazole 10 mg and 20 mg versus placebo for the prevention of endoscopically demonstrable relapse in patients previously diagnosed with erosive or ulcerative gastro-oesophageal reflux disease (GORD) who had no oesophageal erosions or ulcerations at study entry." | 9.09 | Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. ( Birbara, C; Breiter, J; Hahne, W; Perdomo, C, 2000) |
| "To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists." | 9.09 | Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000) |
| "A total of 318 gastroesophageal reflux patients whose erosive esophagitis was healed in a comparative study of esomeprazole 40 mg, 20 mg, or omeprazole 20 mg, were randomized to maintenance therapy with once daily esomeprazole 40 mg, 20 mg, or 10 mg, or placebo in a U." | 9.09 | Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. ( Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J, 2001) |
| "In patients with gastroesophageal reflux disease (GERD), esomeprazole, the S-isomer of omeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the racemic parent compound." | 9.09 | Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. ( Breiter, JR; Hamelin, B; Hwang, C; Johanson, J; Kahrilas, PJ; Levine, JG; Marino, V; Maton, P; Richter, JE, 2001) |
| "To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility." | 9.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis." | 9.09 | Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001) |
| "Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks." | 9.08 | Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996) |
| "Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality." | 9.08 | Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997) |
| "Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 9.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
| "After endoscopy, patients without endoscopic oesophagitis were randomized to omeprazole 20 mg (Ome20), omeprazole 10 mg (Ome10) or placebo once daily for 4 weeks (n = 261) and those with oesophagitis (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n = 277)." | 9.08 | Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. ( Carlsson, R; Dalväg, A; de Groot, G; Dent, J; Hatlebakk, J; Haug, K; Junghard, O; Riley, S; Sheikh, R; van Oudvorst, A; Watts, R; Wiklund, I, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 9.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| " is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis." | 9.08 | Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998) |
| "To investigate the efficacy of daily maintenance treatment with omeprazole 10 mg in reducing the relapse rate of healed erosive oesophagitis." | 9.08 | Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Morris, P; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A; Wason, C, 1998) |
| "Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux." | 9.08 | Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998) |
| "Thirty-four dysphagic patients with peptic stricture and erosive esophagitis were dilated and randomized to omeprazole 20 mg every day versus H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)." | 9.07 | Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. ( Champion, G; Koehler, RE; Marks, RD; Mills, TP; Richter, JE; Rizzo, J; Spenney, JG, 1994) |
| "To determine whether the patients with refractory posterior laryngitis respond to treatment with omeprazole." | 9.07 | Omeprazole for the treatment of posterior laryngitis. ( Hanson, D; Kahrilas, PJ; Kamel, PL, 1994) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 9.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 9.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 9.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole." | 8.82 | Intravenous lansoprazole: in erosive oesophagitis. ( Dando, TM; Plosker, GL, 2004) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "Omeprazole and lansoprazole are used to treat erosive oesophagitis in the respective daily doses of 20 and 30 mg." | 8.81 | Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. ( Howden, CW; Leontiadis, GI; Sharma, VK, 2001) |
| "Individual data from 1154 patients included in five independently conducted, randomized, long-term clinical trials of the efficacy of different dosage regimens of omeprazole, standard ranitidine treatment and placebo for the prevention of relapse of oesophagitis were pooled for this meta-analysis." | 8.79 | Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. ( Carlsson, R; Dent, J; Frison, L; Galmiche, JP; Lundell, L, 1997) |
| "Two cases of esophagitis associated with the use of alendronate are described." | 8.79 | [Alendronate-induced esophagitis. A report of 2 cases]. ( Girelli, CM; Reguzzoni, G; Rocca, F, 1997) |
| "To determine prospectively the dose of omeprazole needed to maintain remission of erosive oesophagitis and reflux symptoms in children." | 7.78 | Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study. ( Hassall, E; Henderson, C; Koletzko, S; Lundborg, P; Radke, M; Shepherd, R, 2012) |
| "Twenty-nine children with moderate to severe erosive oesophagitis and abnormal oesophageal bile reflux were studied before and after treatment with omeprazole 1 mg/kg per day." | 7.73 | Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole. ( Brecelj, J; Heuschkel, R; Homan, M; Orel, R, 2006) |
| "Heartburn was controlled on lansoprazole 30 mg/per day in 76." | 7.72 | Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003) |
| "To evaluate the cost effectiveness of on-demand treatment with esomeprazole 20mg compared with two alternative omeprazole treatment strategies for the long-term management of patients with gastro-oesophageal reflux disease (GORD) without oesophagitis." | 7.71 | Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. ( Green, J; Higgins, A; Junghard, O; Wahlqvist, P, 2002) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 7.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| "To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard." | 7.70 | The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. ( Camargo, L; Fass, R; Fennerty, MB; Ofman, JJ; Sampliner, RE; Wendel, C, 2000) |
| "Forty five patients with refractory oesophagitis, defined as persisting erosive changes or ulceration despite a minimum of three months' treatment with cimetidine 3." | 7.68 | Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine. ( Bardhan, KD; Carroll, NJ; Daly, MJ; Dhande, DS; Hinchliffe, RF; Jones, RB; Morris, P; Thompson, M, 1990) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | 6.71 | On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| " Safety for all study participants was monitored by adverse event reports and laboratory evaluations." | 6.70 | Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002) |
| " Dosing was adjusted by monitoring intragastric pH, and esophagoscopy was repeated after 8-12 weeks of omeprazole treatment." | 6.69 | Histological esophagitis: clinical and histological response to omeprazole in children. ( Calenda, KA; Dayal, Y; Mobassaleh, M; Strauss, RS, 1999) |
| "Both omeprazole doses were significantly superior to placebo in complete endoscopic healing." | 6.67 | Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. ( Ahtaridis, G; Behar, J; Berenson, MM; Hirschowitz, BI; Holt, S; Ippoliti, AF; McCullough, A; Richter, JE; Robinson, MG; Sontag, SJ, 1992) |
| "Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials." | 6.41 | Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002) |
| "Poliprotect proved noninferior to standard-dose omeprazole in symptomatic patients with heartburn/epigastric burning without erosive esophagitis and gastroduodenal lesions." | 5.69 | Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial. ( Annibale, B; Badiali, D; Bassotti, G; Bragazzi, MC; Ciacci, C; Cicala, M; Corazziari, ES; D'Alba, L; D'Ovidio, V; Di Sabatino, A; Gasbarrini, A; Iovino, P; Marazzato, M; Neri, M; Passaretti, S; Radocchia, G; Repici, A; Ribichini, E; Riggio, O; Schippa, S, 2023) |
| "Drug-induced esophagitis is an uncommon diagnosis in the pediatric population." | 5.56 | L-arginine-induced esophagitis, report of six cases. ( Casaubón-Garcín, PR; Ferreiro-Marin, A; González-Cruz, MÁ; Parra, PR, 2020) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 5.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| "Effective treatment of the esophagitis and prevention of stenosis consisted in high doses of omeprazole (1." | 5.31 | High-dose omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia. ( Kerremans, I; Robberecht, E; Van Biervliet, S; Van Winckel, M, 2001) |
| "Cimetidine treatment was successful for seven years but dose reduction was followed by intractable hemorrhage which did not respond to H2-receptor antagonists." | 5.27 | Long term management of hemorrhagic esophagitis with cimetidine and omeprazole. ( Bonnin, M; Hetzel, DJ, 1986) |
| " Here, we compare the efficacy of the gastromucoprotective drug irsogladine with omeprazole in preventing NSAID-induced esophagitis, peptic ulcers, and small-intestinal mucosal injury in healthy subjects." | 5.17 | Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. ( Abe, Y; Higuchi, K; Inoue, T; Ishida, K; Kawakami, K; Kojima, Y; Kuramoto, T; Murano, M; Narabayashi, K; Nouda, S; Takeuchi, T; Tokioka, S; Umegaki, E; Yoda, Y, 2013) |
| " The primary objective was to compare the efficacy of rabeprazole (20 mg) and omeprazole (20 mg) regarding onset of heartburn control during the first 7 days of treatment in patients with erosive oesophagitis." | 5.12 | Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment. ( Bytzer, P; Kennerly, P; Miller, N; Morocutti, A; Ravic, M, 2006) |
| "Patients with chronic GORD and oesophagitis verified at endoscopy were allocated to treatment with omeprazole (154 patients) or antireflux surgery (144)." | 5.12 | Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. ( Hatlebakk, JG; Lundell, L; Malm, A; Miettinen, P; Myrvold, HE; Sutherland, I; Walan, A; Wallin, L, 2007) |
| "A total of 320 patients over 65 years with endoscopically diagnosed esophagitis were randomly assigned to one of the following treatments for 8 wk: (1) omeprazole 20 mg/d; (2) lansoprazole 30 mg/d; (3) pantoprazole 40 mg/d, or (4) rabeprazole 20 mg/d." | 5.12 | Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients. ( Andriulli, A; Annese, V; D'Ambrosio, LP; Di Mario, F; Franceschi, M; Leandro, G; Paris, F; Pilotto, A; Scarcelli, C; Seripa, D, 2007) |
| "Gastro-oesophageal reflux disease patients (349) with endoscopically documented healed erosive oesophagitis (grade 0 or 1) were randomly assigned to receive pantoprazole (10, 20 or 40 mg/q." | 5.11 | Prevention of erosive oesophagitis relapse with pantoprazole. ( Bochenek, W; Fraga, P; Mack, M; Richter, JE; Sabesin, SM, 2004) |
| "To compare the gastric acid inhibition effects of lansoprazole 30 mg administered either intravenous or orally in erosive oesophagitis patients." | 5.11 | Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis. ( Chiu, YL; Kovacs, TO; Lee, CQ; Metz, DC; Pilmer, BL, 2004) |
| "Sixty-seven patients (49 with Zollinger-Ellison syndrome [ZES], 18 without), with basal acid output (BAO) >15 mmol/h or >5 mmol/h if post-antrectomy (n = 9, all ZES), were treated with individually optimized doses of lansoprazole (7." | 5.11 | Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study. ( Hirschowitz, BI; Mohnen, J; Simmons, J, 2005) |
| "To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis." | 5.10 | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis. ( Bochenek, WJ; Metz, DC, 2003) |
| "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age." | 5.10 | Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002) |
| "Gastric and oesophageal pH were determined in 26 subjects with gastro-oesophageal reflux disease at baseline and on days 1, 2 and 8 of treatment with 20 mg omeprazole or 20 mg rabeprazole in a randomized, two-way cross-over fashion." | 5.10 | The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. ( Gallo-Torres, H; Gardner, JD; Miner, PB; Robinson, M; Sloan, S, 2003) |
| "A hypothesis suggesting that profound acid inhibition therapy facilitates and hastens the development of gastric glandular atrophy in patients infected with Helicobacter pylori was investigated in this randomized study comparing omeprazole therapy with antireflux surgery (ARS) for chronic gastroesophageal reflux disease (GERD)." | 5.09 | Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. ( Andersson, A; Hattlebakk, J; Havu, N; Janatuinen, E; Levander, K; Liedman, B; Lundell, L; Miettinen, P; Myrvold, HE; Nyström, P; Pedersen, SA; Thor, K, 1999) |
| "To evaluate the efficacy and tolerability of rabeprazole 10 mg and 20 mg versus placebo for the prevention of endoscopically demonstrable relapse in patients previously diagnosed with erosive or ulcerative gastro-oesophageal reflux disease (GORD) who had no oesophageal erosions or ulcerations at study entry." | 5.09 | Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group. ( Birbara, C; Breiter, J; Hahne, W; Perdomo, C, 2000) |
| "To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists." | 5.09 | Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000) |
| "A total of 318 gastroesophageal reflux patients whose erosive esophagitis was healed in a comparative study of esomeprazole 40 mg, 20 mg, or omeprazole 20 mg, were randomized to maintenance therapy with once daily esomeprazole 40 mg, 20 mg, or 10 mg, or placebo in a U." | 5.09 | Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. ( Benjamin, SB; Damico, D; Goldstein, JL; Hamelin, B; Johnson, DA; Lamet, M; Vakil, NB; Whipple, J, 2001) |
| "In patients with gastroesophageal reflux disease (GERD), esomeprazole, the S-isomer of omeprazole, has demonstrated pharmacological and clinical benefits beyond those seen with the racemic parent compound." | 5.09 | Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. ( Breiter, JR; Hamelin, B; Hwang, C; Johanson, J; Kahrilas, PJ; Levine, JG; Marino, V; Maton, P; Richter, JE, 2001) |
| "To investigate whether pantoprazole also reduces bile reflux and whether this is paralleled by a change in oesophageal motility." | 5.09 | Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis. ( Brundler, R; Gaia, C; Gut, A; Halter, F; Inauen, W; Netzer, P, 2001) |
| "This randomized, double-blind, multicenter study was conducted to confirm a previous finding that lansoprazole relieves heartburn faster than omeprazole in patients with erosive esophagitis." | 5.09 | Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. ( Huang, B; Kahrilas, PJ; Kovacs, TO; Pencyla, JL; Richter, JE; Sontag, SJ, 2001) |
| "Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks." | 5.08 | Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996) |
| " Eighty-eight patients with healed erosive/ulcerative oesophagitis and relief of heartburn after pre-treatment with omeprazole received maintenance treatment." | 5.08 | Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease. ( Aalykke, C; Havelund, T; Rasmussen, L, 1997) |
| "Previous studies have demonstrated greater efficacy for omeprazole compared with cimetidine in patients with endoscopically verified oesophagitis, but excluded the substantial group of gastro-oesophageal reflux disease (GERD) patients with reflux symptoms but without endoscopic abnormality." | 5.08 | Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis. ( Axon, AT; Bate, CM; Emmas, CE; Green, JR; Murray, FE; Taylor, MD; Tildesley, G, 1997) |
| "Following endoscopy 424 patients presenting with heartburn as the predominant symptom of gastro-oesophageal reflux disease were randomized to treatment with omeprazole 20 or 10 mg once daily, or cisapride 10 mg four times daily, in a double-blind, double-dummy, parallel group, multicentre study." | 5.08 | Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. ( Barthelemy, P; Galmiche, JP; Hamelin, B, 1997) |
| "After endoscopy, patients without endoscopic oesophagitis were randomized to omeprazole 20 mg (Ome20), omeprazole 10 mg (Ome10) or placebo once daily for 4 weeks (n = 261) and those with oesophagitis (except circumferential/ulcerative) were randomized to receive either Ome20 or Ome10 once daily for 4 weeks (n = 277)." | 5.08 | Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. ( Carlsson, R; Dalväg, A; de Groot, G; Dent, J; Hatlebakk, J; Haug, K; Junghard, O; Riley, S; Sheikh, R; van Oudvorst, A; Watts, R; Wiklund, I, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 5.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| " is more effective than cimetidine 800 mg nocte in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis." | 5.08 | Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis. ( Axon, AT; Bate, CM; Emmas, C; Green, JR; Murrays, FE; Owen, SM; Taylor, MD; Tildesley, G, 1998) |
| "To investigate the efficacy of daily maintenance treatment with omeprazole 10 mg in reducing the relapse rate of healed erosive oesophagitis." | 5.08 | Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo. ( Bardhan, KD; Bishop, A; Brooks, A; Cherian, P; D'Silva, J; Gillon, KR; Jones, RB; Morris, P; Patterson, J; Polak, J; Thompson, M; Vaishnavi, A; Wason, C, 1998) |
| "Thirteen patients with esophagitis were given omeprazole for 90 days." | 5.08 | Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients. ( Arnestad, JS; Brenna, E; Qvigstad, G; Waldum, HL, 1998) |
| "Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux." | 5.08 | Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998) |
| "Thirty-four dysphagic patients with peptic stricture and erosive esophagitis were dilated and randomized to omeprazole 20 mg every day versus H2RA (ranitidine 150 mg twice daily or famotidine 20 mg twice daily)." | 5.07 | Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. ( Champion, G; Koehler, RE; Marks, RD; Mills, TP; Richter, JE; Rizzo, J; Spenney, JG, 1994) |
| "To determine whether the patients with refractory posterior laryngitis respond to treatment with omeprazole." | 5.07 | Omeprazole for the treatment of posterior laryngitis. ( Hanson, D; Kahrilas, PJ; Kamel, PL, 1994) |
| "Patients (106) with peptic ulceration of the oesophagus, stomach and duodenum, unresponsive to 3 or more months of high-dose treatment with ranitidine, were initially given pantoprazole (40-80 mg, p." | 5.07 | Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Brunner, G; Harke, U, 1994) |
| "Forty-two patients with peptic ulceration of the duodenum, stomach or oesophagus, who had not responded to 3 or more months of high-dose treatment with ranitidine (450 or 600 mg/day), were treated with oral lansoprazole at 30-60 mg daily." | 5.07 | An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. ( Arnold, R; Brunner, G; Fuchs, W; Hennig, U, 1993) |
| "Forty-four patients with esophagitis refractory to standard H2-blocker therapy, who had healed after a 4- to 16-wk course with either 20-40 mg omeprazole or ranitidine at doses of 300-600 mg daily in a randomized double-blind study, commenced a 3-month maintenance course of therapy with 40 mg bid famotidine." | 5.07 | High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study. ( Bianchi-Porro, G; Bonavina, L; Pace, F; Peracchia, A; Sangaletti, O; Termini, R; Vigneri, S, 1991) |
| "An intravenous formulation of lansoprazole, a proton pump inhibitor, is approved for use in patients with erosive oesophagitis who are temporarily unable to take oral lansoprazole." | 4.82 | Intravenous lansoprazole: in erosive oesophagitis. ( Dando, TM; Plosker, GL, 2004) |
| "To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| " The newest PPI, esomeprazole, brings a statistically significant increase in healing of mucosal injury and symptom relief in patients with erosive esophagitis, compared with omeprazole and lansoprazole." | 4.81 | Pharmacologic management of gastroesophageal reflux disease. ( Katz, PO; Ramakrishnan, A, 2002) |
| "To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e." | 4.79 | Lansoprazole: a proton pump inhibitor. ( Garnett, WR, 1996) |
| "Individual data from 1154 patients included in five independently conducted, randomized, long-term clinical trials of the efficacy of different dosage regimens of omeprazole, standard ranitidine treatment and placebo for the prevention of relapse of oesophagitis were pooled for this meta-analysis." | 4.79 | Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. ( Carlsson, R; Dent, J; Frison, L; Galmiche, JP; Lundell, L, 1997) |
| "Two cases of esophagitis associated with the use of alendronate are described." | 4.79 | [Alendronate-induced esophagitis. A report of 2 cases]. ( Girelli, CM; Reguzzoni, G; Rocca, F, 1997) |
| "After antifungal treatment with fluconazole, the patient's clinical symptoms gradually disappeared with the healing of gastric ulcer, which never recurred in this patient until 3 months after follow-up." | 3.91 | A rare case report of fungal esophagitis combined with giant gastric ulcer in an immunocompetent patient. ( Jianping, C; Juan, D; Liang, M; Liwen, Z; Yanbo, D; Yun, Z, 2019) |
| "Twenty-nine children with moderate to severe erosive oesophagitis and abnormal oesophageal bile reflux were studied before and after treatment with omeprazole 1 mg/kg per day." | 3.73 | Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole. ( Brecelj, J; Heuschkel, R; Homan, M; Orel, R, 2006) |
| "Heartburn was controlled on lansoprazole 30 mg/per day in 76." | 3.72 | Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients. ( Abu Farsakh, N, 2003) |
| "To evaluate the cost effectiveness of on-demand treatment with esomeprazole 20mg compared with two alternative omeprazole treatment strategies for the long-term management of patients with gastro-oesophageal reflux disease (GORD) without oesophagitis." | 3.71 | Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies. ( Green, J; Higgins, A; Junghard, O; Wahlqvist, P, 2002) |
| "Patients with grade II-III oesophagitis underwent ambulatory motility/pH monitoring (using a Konigsberg catheter with four pressure transducers at 5 cm intervals) and solid bolus scintigraphy before and after treatment with omeprazole 20 mg b." | 3.70 | The effect of healing oesophagitis on oesophageal motor function as determined by oesophageal scintigraphy and ambulatory oesophageal motility/pH monitoring. ( Collins, JS; Ferguson, WR; Love, AH; McDougall, NI; McFarland, RJ; Mooney, RB, 1998) |
| " We report data from patients with refractory reflux esophagitis who were undergoing maintenance therapy with >/=20 mg omeprazole daily for a mean period of 6." | 3.70 | Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. ( Dent, J; Frame, MH; Havu, N; Klinkenberg-Knol, EC; Lloyd, D; Mitchell, B; Nelis, F; Prichard, P; Romàn, J; Snel, P; Walan, A, 2000) |
| "To compare the omeprazole test to ambulatory 24-h oesophageal pH monitoring in diagnosing GERD in symptomatic patients using endoscopically proven erosive oesophagitis as a gold standard." | 3.70 | The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. ( Camargo, L; Fass, R; Fennerty, MB; Ofman, JJ; Sampliner, RE; Wendel, C, 2000) |
| "In a previous study we reported lack of improvement in oesophageal motor function after complete healing of oesophagitis achieved by treatment with omeprazole for a median duration of 12 weeks." | 3.69 | Prolonged remission of oesophagitis does not alter the magnitude of oesophageal acid exposure. ( Colin-Jones, DG; Singh, P; Taylor, RH, 1994) |
| "To investigate whether healing of the esophagitis was associated with an improvement in esophageal clearance function, 15 patients with endoscopic and histologically confirmed erosive esophagitis were studied both before and after 1-month treatment with 40 mg/day of omeprazole." | 3.69 | Esophageal clearance function following treatment of esophagitis. ( Bancewicz, J; Heggie, L; O'Hanrahan, T; Thompson, DG; Williams, D, 1994) |
| " Gastrin cells are normally inhibited by gastric acid and in this study we have examined how suppression of acid by treatment with omeprazole for 6-8 weeks influences gastrin production in patients with oesophagitis." | 3.68 | Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole. ( Bridson, J; Dockray, GJ; Nemeth, J; Varro, A; Walker, R, 1992) |
| "Dysphonia is a significant problem in GER." | 2.75 | Effectiveness of voice therapy in reflux-related voice disorders. ( Bhatia, SJ; Gore, G; Hattiangadi, G; Keer, V; Murugesh, M; Ramesh, VS; Sandur, V; Vashani, K, 2010) |
| "Fifty-five patients (17 with nonerosive GERD and 38 with low-grade esophagitis) were treated with rabeprazole, 20 mg/day." | 2.71 | On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction. ( Argüello, L; Bastida, G; Garrigues, V; Ortiz, V; Ponce, J; Ponce, M, 2004) |
| " Safety for all study participants was monitored by adverse event reports and laboratory evaluations." | 2.70 | Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002) |
| " Dosing was adjusted by monitoring intragastric pH, and esophagoscopy was repeated after 8-12 weeks of omeprazole treatment." | 2.69 | Histological esophagitis: clinical and histological response to omeprazole in children. ( Calenda, KA; Dayal, Y; Mobassaleh, M; Strauss, RS, 1999) |
| "Posttreatment clarithromycin resistance is common in patients who do not experience success with therapy." | 2.68 | Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. ( Axon, AT; Chalmers, DM; Dixon, MF; Langworthy, H; Moayyedi, P; Shanahan, K; Tompkins, DS, 1996) |
| "Omeprazole was superior to placebo in healing of esophagitis." | 2.67 | Macroscopic healing of esophagitis does not improve esophageal motility. ( Bondy, DC; Flowers, MA; Frei, JV; Howard, JM; McDonald, TJ; Reynolds, RP; Tilbe, K, 1994) |
| "Both omeprazole doses were significantly superior to placebo in complete endoscopic healing." | 2.67 | Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study. ( Ahtaridis, G; Behar, J; Berenson, MM; Hirschowitz, BI; Holt, S; Ippoliti, AF; McCullough, A; Richter, JE; Robinson, MG; Sontag, SJ, 1992) |
| "Pediatric patients with gastroesophageal reflux disease and certain chronic comorbidities appear to have the greatest need of maintenance PPI treatment after healing of reflux esophagitis." | 2.46 | Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis. ( Henderson, C; Illueca, M; Lundborg, P; Wernersson, B, 2010) |
| "Esomeprazole 40 mg was found to provide significantly higher healing rates at 4 weeks [OR 1." | 2.45 | Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials. ( DAS, R; Edwards, SJ; Lind, T; Lundell, L, 2009) |
| "To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects." | 2.43 | Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "It has been shown that GERD has a significant impact on patients' quality of life; therefore, improvement of quality of life is one of the major goals of GERD treatment." | 2.42 | The impact of gastroesophageal reflux disease on quality of life. ( Kamolz, T; Pointner, R; Velanovich, V, 2003) |
| "Rabeprazole is a newer generation proton pump inhibitor that suppresses the gastric proton pump and acid secretion more rapidly than does omeprazole, lansoprazole or pantoprazole." | 2.42 | Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment. ( Miner, P, 2004) |
| "It is more effective in treating erosive esophagitis in patients with GERD than omeprazole." | 2.41 | Esomeprazole magnesium (Nexium). ( Baker, DE, 2001) |
| "Esomeprazole is an effective agent in the treatment of gastroesophageal reflux disease (GERD) and erosive esophagitis." | 2.41 | Esomeprazole: update and clinical review. ( Baker, DE, 2002) |
| "Pantoprazole is a gastric hydrogen-potassium adenosine triphosphatase (H+/K(+)-ATPase) inhibitor." | 2.41 | Pantoprazole. ( Poole, P, 2001) |
| "Gastroesophageal reflux is a normal phenomenon recognized in infants as "spitting up." | 2.41 | Gastroesophageal reflux in infants and children. When to reassure and when to go further. ( Jones, AB, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Lansoprazole has a wide margin of safety and is well tolerated when administered as monotherapy in short- and long-term clinical trials." | 2.41 | Lansoprazole for maintenance of remission of erosive oesophagitis. ( Ballard, ED; Freston, JW; Huang, B; Jackson, RL, 2002) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion." | 2.40 | Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. ( Langtry, HD; Wilde, MI, 1997) |
| "Reflux esophagitis is a chronic condition and after stopping antisecretory treatment, including lansoprazole, most patients relapse in terms of symptoms and endoscopical lesions, which suggests the need for long-term treatment." | 2.38 | Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. ( Di Fede, F; Dobrilla, G, 1993) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "Drug-induced esophagitis is an uncommon diagnosis in the pediatric population." | 1.56 | L-arginine-induced esophagitis, report of six cases. ( Casaubón-Garcín, PR; Ferreiro-Marin, A; González-Cruz, MÁ; Parra, PR, 2020) |
| " It is unclear if polymyositis was triggered by interaction of the statin with omeprazole and/or gemfibrozil, or if it developed secondary to long-term use of atorvastatin only." | 1.39 | Statin-associated polymyositis following omeprazole treatment. ( Flores, RM; Kanth, R; Shah, MS, 2013) |
| " However, as with all drugs, PPIs should be dosed appropriately, and should be reserved for patients with conditions for which there is clear evidence of benefit from therapy." | 1.36 | Editorial: just how "difficult" is it to withdraw PPI treatment? ( Howden, CW; Kahrilas, PJ, 2010) |
| "Pre-existing nonerosive gastroesophageal reflux disease, smoking, and older age are important predictors of de novo development of erosive esophagitis." | 1.36 | De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupčinskas, J; Kupčinskas, L, 2010) |
| "Gastroesophageal reflux is a well-recognized complication of obesity." | 1.35 | Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND. ( Chang, CG; Perez, E, 2009) |
| " A retrospective review of children receiving PPI therapy continuously for 1 year or more with baseline and follow-up esophageal and gastric biopsies on treatment was conducted to assess type, frequency, and duration of PPI dosing, symptom relief, gastrin levels, histologic findings, and adverse events." | 1.35 | Long-term proton pump inhibitor use in children: a retrospective review of safety. ( Boyer, K; Tolia, V, 2008) |
| "To determine the role of duodenogastro-esophageal reflux (DGER) in the pathogenesis of refractory gastro-esophageal reflux disease (GERD) in children." | 1.34 | Duodenogastro-esophageal reflux in children with refractory gastro-esophageal reflux disease. ( De Greef, T; Ectors, N; Haesendonck, N; Hoffman, I; Tack, J; Tertychnyy, A, 2007) |
| "Oesophagitis was induced by pyloric ligation in wild-type and VR-1 deficient mice." | 1.33 | Attenuation of acid induced oesophagitis in VR-1 deficient mice. ( de la Fuente, SG; Fujino, K; Mantyh, CR; Takahashi, T; Takami, Y, 2006) |
| "Cough was significantly less severe in NEE adolescents than in younger children." | 1.33 | Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006) |
| "We report on two patients with schizoaffective disorder who received omeprazole in addition to clozapine because of gastrointestinal complaints." | 1.32 | Omeprazole reduces clozapine plasma concentrations. A case report. ( Bergemann, N; Frick, A; Kopitz, J, 2003) |
| "In refractory cases of GERD, eosinophilic esophagitis must be considered before any surgical measure." | 1.32 | Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice. ( Cury, EK; Faintuch, S; Schraibman, V, 2004) |
| "pylori and oesophagitis is mediated by the effect of H." | 1.31 | Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease? ( Bianchi Porro, G; Pace, F, 2000) |
| "Effective treatment of the esophagitis and prevention of stenosis consisted in high doses of omeprazole (1." | 1.31 | High-dose omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia. ( Kerremans, I; Robberecht, E; Van Biervliet, S; Van Winckel, M, 2001) |
| "Omeprazole has shown remarkable efficacy and safety in the treatment of patients with gastroesophageal reflux disease (GERD); similarly, laparoscopic techniques have allowed less morbidity in patients undergoing fundoplication procedures." | 1.30 | Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. ( Centor, RM; Heudebert, GR; Marks, R; Wilcox, CM, 1997) |
| "Cytology from Barrett's esophagus can be misleading in the presence of severe inflammation." | 1.30 | Brush cytology in the diagnosis of neoplasia in Barrett's esophagus. ( Alderson, D; Hardwick, RH; Lott, M; Morgan, RJ; Warren, BF, 1997) |
| "Reflux esophagitis is frequently associated with peristaltic dysfunction, which increases with the severity of inflammatory lesions." | 1.30 | Healing of severe esophagitis improves esophageal peristaltic dysfunction. ( Deprez, P; Fiasse, R, 1999) |
| " The pharmacokinetic parameters of omeprazole were: systemic clearance, 0." | 1.29 | Pharmacokinetics of intravenous omeprazole in children. ( Andre, J; Baudouin, V; Bellaich, M; Faure, C; Jacqz-Aigrain, E; Navarro, J; Rohrlich, P, 1994) |
| "Oesophagitis was treated with omeprazole 40 mg/day for a median duration of 12 weeks." | 1.28 | Oesophageal motor function before and after healing of oesophagitis. ( Adamopoulos, A; Colin-Jones, DG; Singh, P; Taylor, RH, 1992) |
| "Cimetidine treatment was successful for seven years but dose reduction was followed by intractable hemorrhage which did not respond to H2-receptor antagonists." | 1.27 | Long term management of hemorrhagic esophagitis with cimetidine and omeprazole. ( Bonnin, M; Hetzel, DJ, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (2.26) | 18.7374 |
| 1990's | 69 (38.98) | 18.2507 |
| 2000's | 84 (47.46) | 29.6817 |
| 2010's | 16 (9.04) | 24.3611 |
| 2020's | 4 (2.26) | 2.80 |
| Authors | Studies |
|---|---|
| Vaezi, MF | 1 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 3 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 2 |
| Corazziari, ES | 1 |
| Gasbarrini, A | 1 |
| D'Alba, L | 1 |
| D'Ovidio, V | 1 |
| Riggio, O | 1 |
| Passaretti, S | 1 |
| Annibale, B | 1 |
| Cicala, M | 1 |
| Repici, A | 1 |
| Bassotti, G | 1 |
| Ciacci, C | 1 |
| Di Sabatino, A | 1 |
| Neri, M | 1 |
| Bragazzi, MC | 1 |
| Ribichini, E | 1 |
| Radocchia, G | 1 |
| Iovino, P | 1 |
| Marazzato, M | 1 |
| Schippa, S | 1 |
| Badiali, D | 1 |
| Roa Colomo, A | 1 |
| García Robles, A | 1 |
| Ruiz Escolano, E | 1 |
| Levy, AN | 1 |
| Ali, N | 1 |
| Andrici, J | 1 |
| Hamilton, MJ | 1 |
| Parra, PR | 1 |
| González-Cruz, MÁ | 1 |
| Ferreiro-Marin, A | 1 |
| Casaubón-Garcín, PR | 1 |
| Liang, M | 1 |
| Liwen, Z | 1 |
| Juan, D | 1 |
| Yun, Z | 1 |
| Yanbo, D | 1 |
| Jianping, C | 1 |
| Mazzoleni, F | 1 |
| Mazzoleni, LE | 1 |
| de Magalhães Francesconi, CF | 1 |
| Sander, GB | 1 |
| Von Reisswitz, PS | 1 |
| Milbradt, TC | 1 |
| da Veiga Chaves Picon, R | 1 |
| Uchoa, DM | 1 |
| De Bona, LR | 1 |
| Andreolla, HF | 1 |
| Breyer, HP | 1 |
| Spinato Torresini, R | 1 |
| Ott, EA | 1 |
| Wortmann, AC | 1 |
| de Lucena Theil, A | 1 |
| Stifft, J | 1 |
| Zenker, RP | 1 |
| Krumel, CF | 1 |
| Michalczuk, MT | 1 |
| De Araujo, A | 1 |
| Canevese, AP | 1 |
| Volpato, N | 1 |
| da Silva, CA | 1 |
| Schaefer, PG | 1 |
| Titton, NF | 1 |
| Longo, L | 1 |
| Edelweiss, MI | 1 |
| Simon, D | 1 |
| Talley, NJ | 1 |
| Beales, ILP | 1 |
| Kanth, R | 1 |
| Shah, MS | 1 |
| Flores, RM | 1 |
| Kuramoto, T | 1 |
| Umegaki, E | 1 |
| Nouda, S | 1 |
| Narabayashi, K | 1 |
| Kojima, Y | 1 |
| Yoda, Y | 1 |
| Ishida, K | 1 |
| Kawakami, K | 1 |
| Abe, Y | 1 |
| Takeuchi, T | 1 |
| Inoue, T | 1 |
| Murano, M | 1 |
| Tokioka, S | 1 |
| Higuchi, K | 1 |
| Banerjee, R | 1 |
| Reddy, DN | 1 |
| Castelluccio, MS | 1 |
| Hermida, R | 1 |
| Ayunta, H | 1 |
| Manzotti, L | 1 |
| Cháves, E | 1 |
| Romo, R | 1 |
| Perelstein, G | 1 |
| Vashani, K | 1 |
| Murugesh, M | 1 |
| Hattiangadi, G | 1 |
| Gore, G | 1 |
| Keer, V | 1 |
| Ramesh, VS | 1 |
| Sandur, V | 1 |
| Bhatia, SJ | 1 |
| Edwards, SJ | 1 |
| Lind, T | 2 |
| Lundell, L | 5 |
| DAS, R | 1 |
| Vandenplas, Y | 1 |
| Hauser, B | 1 |
| Devreker, T | 1 |
| Urbain, D | 1 |
| Reynaert, H | 1 |
| Cohen, H | 1 |
| Tomasso, G | 1 |
| Luisa Cafferata, M | 1 |
| Zapata, C | 1 |
| Sharma, P | 1 |
| Armstrong, D | 1 |
| Moraes-Filho, JP | 1 |
| Blasco, C | 1 |
| Corti, R | 1 |
| Estape, G | 1 |
| Leite Luna, L | 1 |
| Ortuño, R | 1 |
| Sakai, P | 1 |
| Salis, G | 1 |
| Taullard, D | 1 |
| Trakal, E | 1 |
| Valdovinos, M | 1 |
| Vergara, M | 1 |
| Gónzalez, O | 1 |
| González F, CG | 1 |
| Torres, J | 1 |
| Molina U, R | 1 |
| Harris, PR | 1 |
| Chang, CG | 1 |
| Perez, E | 1 |
| Yaghoobi, M | 1 |
| Padol, S | 1 |
| Yuan, Y | 1 |
| Hunt, RH | 1 |
| de Leone, A | 2 |
| Tonini, M | 2 |
| Dominici, P | 2 |
| Grossi, E | 2 |
| Pace, F | 4 |
| Kahrilas, PJ | 4 |
| Illueca, M | 1 |
| Wernersson, B | 1 |
| Henderson, C | 2 |
| Lundborg, P | 2 |
| Jonaitis, L | 1 |
| Kupčinskas, J | 1 |
| Kiudelis, G | 1 |
| Kupčinskas, L | 1 |
| Bjornsson, E | 1 |
| Riegler, G | 1 |
| Hassall, E | 4 |
| Shepherd, R | 1 |
| Koletzko, S | 1 |
| Radke, M | 1 |
| Baker, DE | 2 |
| Dabney-Smith, K | 1 |
| Nam, J | 1 |
| Ghazale, A | 1 |
| Cai, Q | 1 |
| Metz, DC | 3 |
| Bochenek, WJ | 2 |
| Siupsinskiene, N | 1 |
| Adamonis, K | 1 |
| Orr, CF | 1 |
| Rowe, DB | 1 |
| Tolia, V | 3 |
| Fitzgerald, J | 1 |
| Huang, B | 4 |
| Pilmer, B | 1 |
| Kane, R | 1 |
| Ferry, G | 1 |
| Gunasekaran, T | 1 |
| Keith, R | 1 |
| Book, L | 1 |
| Ramaswamy, K | 1 |
| Jacobson, K | 1 |
| Jevon, G | 1 |
| Israel, D | 1 |
| Karlstadt, RG | 1 |
| Walker, K | 1 |
| Kamolz, T | 1 |
| Pointner, R | 1 |
| Velanovich, V | 1 |
| Frick, A | 1 |
| Kopitz, J | 1 |
| Bergemann, N | 1 |
| Gardner, JD | 1 |
| Gallo-Torres, H | 1 |
| Sloan, S | 1 |
| Robinson, M | 1 |
| Miner, PB | 1 |
| Füessl, HS | 3 |
| Orr, WC | 1 |
| Abu Farsakh, N | 1 |
| Cury, EK | 1 |
| Schraibman, V | 1 |
| Faintuch, S | 1 |
| Kountouras, J | 1 |
| Zavos, C | 1 |
| Chatzopoulos, D | 1 |
| Ponce, J | 1 |
| Argüello, L | 1 |
| Bastida, G | 1 |
| Ponce, M | 1 |
| Ortiz, V | 1 |
| Garrigues, V | 1 |
| Richter, JE | 6 |
| Fraga, P | 1 |
| Mack, M | 1 |
| Sabesin, SM | 1 |
| Bochenek, W | 1 |
| Dando, TM | 1 |
| Plosker, GL | 1 |
| Kovacs, TO | 2 |
| Lee, CQ | 1 |
| Chiu, YL | 2 |
| Pilmer, BL | 1 |
| Miner, P | 1 |
| Mack, ME | 1 |
| Fraga, PD | 1 |
| Katz, PO | 2 |
| Hirschowitz, BI | 2 |
| Simmons, J | 1 |
| Mohnen, J | 1 |
| Fossmark, R | 1 |
| Johnsen, G | 1 |
| Johanessen, E | 1 |
| Waldum, HL | 2 |
| Rahhal, RM | 1 |
| Ramkumar, DP | 1 |
| Pashankar, DS | 1 |
| Calabrese, C | 1 |
| Bortolotti, M | 1 |
| Fabbri, A | 1 |
| Areni, A | 1 |
| Cenacchi, G | 1 |
| Scialpi, C | 1 |
| Miglioli, M | 1 |
| Di Febo, G | 1 |
| Wang, WH | 1 |
| Huang, JQ | 1 |
| Zheng, GF | 1 |
| Xia, HH | 1 |
| Wong, WM | 1 |
| Lam, SK | 1 |
| Wong, BC | 1 |
| Fujino, K | 1 |
| de la Fuente, SG | 1 |
| Takami, Y | 1 |
| Takahashi, T | 1 |
| Mantyh, CR | 1 |
| Sgouros, SN | 1 |
| Mantides, A | 1 |
| Sostek, MB | 1 |
| Hwang, C | 2 |
| Orel, R | 1 |
| Brecelj, J | 1 |
| Homan, M | 1 |
| Heuschkel, R | 1 |
| Gupta, SK | 1 |
| Amer, F | 1 |
| Heyman, MB | 2 |
| Teraishi, F | 1 |
| Fujiwara, T | 1 |
| Jikuhara, A | 1 |
| Kamitani, S | 1 |
| Morino, Y | 1 |
| Sato, K | 1 |
| Tanaka, N | 1 |
| Bytzer, P | 1 |
| Morocutti, A | 1 |
| Kennerly, P | 1 |
| Ravic, M | 1 |
| Miller, N | 1 |
| Guimarães, EV | 1 |
| Marguet, C | 1 |
| Camargos, PA | 1 |
| Miettinen, P | 2 |
| Myrvold, HE | 2 |
| Hatlebakk, JG | 2 |
| Wallin, L | 1 |
| Malm, A | 1 |
| Sutherland, I | 1 |
| Walan, A | 2 |
| Lassen, AT | 1 |
| Quigley, EM | 1 |
| Boyer, K | 1 |
| Hoffman, I | 1 |
| Tertychnyy, A | 1 |
| Ectors, N | 1 |
| De Greef, T | 1 |
| Haesendonck, N | 1 |
| Tack, J | 1 |
| Pilotto, A | 1 |
| Franceschi, M | 1 |
| Leandro, G | 1 |
| Scarcelli, C | 1 |
| D'Ambrosio, LP | 1 |
| Paris, F | 1 |
| Annese, V | 1 |
| Seripa, D | 1 |
| Andriulli, A | 1 |
| Di Mario, F | 1 |
| Dam, C | 1 |
| Bygum, A | 1 |
| Gil-Simón, P | 1 |
| Barrio, J | 1 |
| Saracíbar, E | 1 |
| Pérez-Miranda, M | 1 |
| Julián, L | 1 |
| Antonio Gil Ruiz, J | 1 |
| Caro-Patón, A | 1 |
| Cadiot, G | 1 |
| Hélie, C | 1 |
| Vallot, T | 2 |
| Marmuse, JP | 1 |
| Cosnes, J | 1 |
| Riché, A | 1 |
| Mignon, M | 2 |
| Collen, MJ | 1 |
| Strong, RM | 1 |
| Rabeneck, L | 1 |
| Marks, RD | 1 |
| Rizzo, J | 1 |
| Koehler, RE | 1 |
| Spenney, JG | 1 |
| Mills, TP | 1 |
| Champion, G | 1 |
| Jacqz-Aigrain, E | 1 |
| Bellaich, M | 1 |
| Faure, C | 1 |
| Andre, J | 1 |
| Rohrlich, P | 1 |
| Baudouin, V | 1 |
| Navarro, J | 1 |
| Dobrilla, G | 1 |
| Di Fede, F | 1 |
| Fass, R | 2 |
| Mackel, C | 1 |
| Sampliner, RE | 2 |
| Nelis, GF | 1 |
| Engelage, AH | 1 |
| Samson, G | 1 |
| Nousbaum, JB | 1 |
| Berthou, F | 1 |
| Carlhant, D | 1 |
| Riche, C | 1 |
| Robaszkiewicz, M | 1 |
| Gouerou, H | 1 |
| Singh, P | 2 |
| Taylor, RH | 2 |
| Colin-Jones, DG | 2 |
| Howard, JM | 1 |
| Reynolds, RP | 1 |
| Frei, JV | 1 |
| Flowers, MA | 1 |
| McDonald, TJ | 1 |
| Tilbe, K | 1 |
| Bondy, DC | 1 |
| Kamel, PL | 1 |
| Hanson, D | 1 |
| Ducrotté, P | 1 |
| Guillemot, F | 1 |
| Elouaer-Blanc, L | 1 |
| Hirschauer, C | 1 |
| Thorel, JM | 1 |
| Petit, A | 1 |
| Hochain, P | 1 |
| Michel, P | 1 |
| Cortot, A | 1 |
| Colin, R | 1 |
| Brunner, G | 2 |
| Harke, U | 1 |
| Williams, D | 1 |
| Thompson, DG | 1 |
| Heggie, L | 1 |
| O'Hanrahan, T | 1 |
| Bancewicz, J | 1 |
| Watson, A | 1 |
| Arnold, R | 1 |
| Hennig, U | 1 |
| Fuchs, W | 1 |
| Alliët, P | 1 |
| Raes, M | 1 |
| Gillis, P | 1 |
| Callewaert, M | 1 |
| Zimmermann, A | 1 |
| Sarda, H | 1 |
| Allisy, C | 1 |
| Le Loc'h, H | 1 |
| Benhamou, PH | 1 |
| Vannerom, PY | 1 |
| Caussignac, Y | 1 |
| Martin, S | 1 |
| Jobin, G | 1 |
| Beauchamp, G | 1 |
| Mee, AS | 1 |
| Rowley, JL | 1 |
| Garnett, WR | 1 |
| Heudebert, GR | 1 |
| Marks, R | 1 |
| Wilcox, CM | 1 |
| Centor, RM | 1 |
| Havelund, T | 2 |
| Aalykke, C | 1 |
| Rasmussen, L | 1 |
| Jaspersen, D | 2 |
| Keerl, R | 1 |
| Weber, R | 1 |
| Huppmann, A | 1 |
| Hammar, CH | 1 |
| Draf, W | 1 |
| Carlsson, R | 4 |
| Galmiche, JP | 3 |
| Dent, J | 3 |
| Frison, L | 1 |
| Girelli, CM | 1 |
| Reguzzoni, G | 1 |
| Rocca, F | 1 |
| Langtry, HD | 1 |
| Wilde, MI | 1 |
| Rencken, IO | 1 |
| Perr, HA | 1 |
| Gooding, CA | 1 |
| Bate, CM | 2 |
| Green, JR | 2 |
| Axon, AT | 3 |
| Murray, FE | 1 |
| Tildesley, G | 2 |
| Emmas, CE | 1 |
| Taylor, MD | 2 |
| Barthelemy, P | 1 |
| Hamelin, B | 3 |
| Borum, ML | 1 |
| Cannava, M | 1 |
| Moayyedi, P | 1 |
| Langworthy, H | 1 |
| Shanahan, K | 1 |
| Tompkins, DS | 1 |
| Dixon, MF | 1 |
| Chalmers, DM | 1 |
| Hardwick, RH | 1 |
| Morgan, RJ | 1 |
| Warren, BF | 1 |
| Lott, M | 1 |
| Alderson, D | 1 |
| Franko, TG | 1 |
| el-Nujumi, A | 1 |
| Williams, C | 1 |
| Ardill, JE | 1 |
| Oien, K | 1 |
| McColl, KE | 1 |
| Walters, JK | 1 |
| Zimmermann, AE | 1 |
| Souney, PF | 1 |
| Katona, BG | 1 |
| Watts, R | 1 |
| Riley, S | 1 |
| Sheikh, R | 1 |
| Hatlebakk, J | 1 |
| Haug, K | 1 |
| de Groot, G | 1 |
| van Oudvorst, A | 1 |
| Dalväg, A | 1 |
| Junghard, O | 3 |
| Wiklund, I | 1 |
| Berstad, A | 1 |
| Murrays, FE | 1 |
| Owen, SM | 1 |
| Emmas, C | 1 |
| McDougall, NI | 1 |
| Mooney, RB | 1 |
| Ferguson, WR | 1 |
| Collins, JS | 1 |
| McFarland, RJ | 1 |
| Love, AH | 1 |
| Israel, DM | 1 |
| Bardhan, KD | 2 |
| Cherian, P | 1 |
| Vaishnavi, A | 1 |
| Jones, RB | 2 |
| Thompson, M | 2 |
| Morris, P | 2 |
| Brooks, A | 1 |
| D'Silva, J | 1 |
| Gillon, KR | 1 |
| Wason, C | 1 |
| Patterson, J | 1 |
| Polak, J | 1 |
| Bishop, A | 1 |
| Qvigstad, G | 1 |
| Arnestad, JS | 1 |
| Brenna, E | 1 |
| Janczewska, I | 2 |
| Sagar, M | 2 |
| Sjöstedt, S | 1 |
| Hammarlund, B | 1 |
| Iwarzon, M | 1 |
| Seensalu, R | 2 |
| Deprez, P | 1 |
| Fiasse, R | 1 |
| Strauss, RS | 1 |
| Calenda, KA | 1 |
| Dayal, Y | 1 |
| Mobassaleh, M | 1 |
| Bloom, BS | 1 |
| Hillman, AL | 1 |
| LaMont, B | 1 |
| Liss, C | 1 |
| Schwartz, JS | 1 |
| Stever, GJ | 1 |
| Ljungdahl, A | 1 |
| Bertilsson, L | 1 |
| Glise, H | 1 |
| Lauritsen, K | 1 |
| Pedersen, SA | 2 |
| Anker-Hansen, O | 1 |
| Stubberöd, A | 1 |
| Eriksson, G | 1 |
| Cockayne, SE | 1 |
| Glet, RJ | 1 |
| Gawkrodger, DJ | 1 |
| McDonagh, AJ | 1 |
| Thor, K | 1 |
| Andersson, A | 1 |
| Hattlebakk, J | 1 |
| Havu, N | 2 |
| Janatuinen, E | 1 |
| Levander, K | 1 |
| Liedman, B | 1 |
| Nyström, P | 1 |
| Diehl, KL | 1 |
| Geyer, P | 1 |
| Martens, E | 1 |
| Sipilä, J | 1 |
| Parkkola, R | 1 |
| Varpula, M | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Sammer, D | 1 |
| Lee, E | 1 |
| Martín de Argila, C | 1 |
| Boixeda de Miquel, D | 1 |
| Moreira Vicente, V | 1 |
| García Plaza, A | 1 |
| Klinkenberg-Knol, EC | 1 |
| Nelis, F | 1 |
| Snel, P | 1 |
| Mitchell, B | 1 |
| Prichard, P | 1 |
| Lloyd, D | 1 |
| Frame, MH | 1 |
| Romàn, J | 1 |
| Chocarro Martínez, A | 1 |
| Galindo Tobal, F | 1 |
| Ruiz-Irastorza, G | 1 |
| González López, A | 1 |
| Alvarez Navia, F | 1 |
| Ochoa Sangrador, C | 1 |
| Martín Arribas, MI | 1 |
| Ofman, JJ | 1 |
| Camargo, L | 1 |
| Wendel, C | 1 |
| Fennerty, MB | 1 |
| Vernet Vernet, M | 1 |
| Roca Figueras, G | 1 |
| Jovell Fernández, E | 1 |
| Iglesias Rodríguez, M | 1 |
| Ureña Tapia, MM | 1 |
| Roca Fusalba, A | 1 |
| Bianchi Porro, G | 1 |
| Birbara, C | 1 |
| Breiter, J | 1 |
| Perdomo, C | 1 |
| Hahne, W | 1 |
| Holloway, RH | 1 |
| Franco, MT | 1 |
| Salvia, G | 1 |
| Terrin, G | 1 |
| Spadaro, R | 1 |
| De Rosa, I | 1 |
| Iula, VD | 1 |
| Cucchiara, S | 1 |
| Todd, JA | 1 |
| Weston, T | 1 |
| MacDonald, TM | 1 |
| Johnston, DA | 1 |
| Dillon, JF | 1 |
| Sharma, VK | 1 |
| Leontiadis, GI | 1 |
| Johnson, DA | 1 |
| Benjamin, SB | 1 |
| Vakil, NB | 1 |
| Goldstein, JL | 1 |
| Lamet, M | 1 |
| Whipple, J | 1 |
| Damico, D | 1 |
| Schwetz, BA | 1 |
| Johanson, J | 1 |
| Maton, P | 1 |
| Breiter, JR | 1 |
| Marino, V | 1 |
| Levine, JG | 1 |
| Poole, P | 1 |
| Van Biervliet, S | 1 |
| Van Winckel, M | 1 |
| Robberecht, E | 1 |
| Kerremans, I | 1 |
| Netzer, P | 1 |
| Gut, A | 1 |
| Brundler, R | 1 |
| Gaia, C | 1 |
| Halter, F | 1 |
| Inauen, W | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Mulder, CJ | 1 |
| Nusteling, K | 1 |
| Sontag, SJ | 2 |
| Pencyla, JL | 1 |
| Jones, AB | 1 |
| Maekawa, T | 1 |
| Ohji, G | 1 |
| Inoue, R | 1 |
| Shimoyama, M | 1 |
| Shimada, T | 1 |
| Misaki, F | 1 |
| Vigneri, S | 2 |
| Scarpignato, C | 1 |
| Savarino, V | 1 |
| Lu, CL | 1 |
| Chen, TS | 1 |
| Chen, CY | 1 |
| Chang, FY | 1 |
| Kang, LJ | 1 |
| Lee, SD | 1 |
| Hinder, RA | 1 |
| Bown, RL | 1 |
| Wahlqvist, P | 1 |
| Higgins, A | 1 |
| Green, J | 1 |
| Freston, JW | 1 |
| Jackson, RL | 1 |
| Ballard, ED | 1 |
| Ramakrishnan, A | 1 |
| Sheth, NP | 1 |
| Varughese, LA | 1 |
| Mazur, LJ | 1 |
| Lawn, SD | 1 |
| Venkatesan, P | 1 |
| Kaloustian, E | 1 |
| Veyssier, P | 1 |
| Nemeth, J | 1 |
| Varro, A | 1 |
| Bridson, J | 1 |
| Walker, R | 1 |
| Dockray, GJ | 1 |
| Adamopoulos, A | 1 |
| Gouilloud-Celle, S | 1 |
| Dutertre, JP | 1 |
| Soutif, D | 1 |
| Jonville, AP | 1 |
| Cadenne, M | 1 |
| Valat, JP | 1 |
| Autret, E | 1 |
| Holt, S | 1 |
| Robinson, MG | 1 |
| Behar, J | 1 |
| Berenson, MM | 1 |
| McCullough, A | 1 |
| Ippoliti, AF | 1 |
| Ahtaridis, G | 1 |
| Zeitoun, P | 1 |
| Thiéfin, G | 1 |
| Duchateau, A | 1 |
| Diébold, MD | 1 |
| Bianchi-Porro, G | 1 |
| Sangaletti, O | 1 |
| Peracchia, A | 1 |
| Bonavina, L | 1 |
| Termini, R | 1 |
| Marinos, Y | 1 |
| Honson, K | 1 |
| Hostein, J | 1 |
| Li, V | 1 |
| Carpentier, P | 1 |
| Fournet, J | 1 |
| Dhande, DS | 1 |
| Hinchliffe, RF | 1 |
| Daly, MJ | 1 |
| Carroll, NJ | 1 |
| Mazure, PA | 1 |
| Pigliacampo, J | 1 |
| Olive, A | 1 |
| Maddison, PJ | 1 |
| Davis, M | 1 |
| Wormsley, KG | 1 |
| Hetzel, DJ | 1 |
| Bonnin, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long-Term Study of the Efficacy and Safety of Lansoprazole in the Treatment of Zollinger-Ellison and Other Acid Hypersecretors[NCT00204373] | Phase 4 | 72 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| Capsaicin-sensitive Transient Receptor Potential Vanilloid One (TRPV1) and Tyrosine Kinase (TrkA) Receptor Expression in Children With Retrosternal Pain[NCT00677378] | 77 participants (Actual) | Observational | 2006-12-31 | Completed | |||
| Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study[NCT02081404] | 98 participants (Actual) | Interventional | 2009-03-01 | Completed | |||
| Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis[NCT01524757] | 48 participants (Anticipated) | Interventional | 2012-03-31 | Not yet recruiting | |||
| Study of a Dietary Supplement for Reflux During Sleep[NCT02274636] | 50 participants (Anticipated) | Interventional | 2014-10-31 | Not yet recruiting | |||
| A Phase I, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of Multiple Oral Doses of H008 (Carenoprazan Hydrochloride Tablets) in Healthy Volunteers[NCT05050188] | Phase 1 | 24 participants (Actual) | Interventional | 2021-06-24 | Completed | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
number of participants with control of gastric acid production (NCT00204373)
Timeframe: up to 240 months from study enrollment
| Intervention | participants (Number) |
|---|---|
| Single Group | 72 |
The median survival from the time of diagnosis (NCT00204373)
Timeframe: survival or up to 240 months
| Intervention | years (Median) |
|---|---|
| Single Group | 6.6 |
36 reviews available for omeprazole and Esophagitis
| Article | Year |
|---|---|
Systematic review: standard- and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis -- a mixed treatment comparison of randomized controlled trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esomep | 2009 |
Latin american consensus on gastroesophageal reflux disease: an update on therapy.
Topics: Alginates; Antacids; Anti-Ulcer Agents; Cohort Studies; Consensus; Dose-Response Relationship, Drug; | 2010 |
Impact of oesophagitis classification in evaluating healing of erosive oesophagitis after therapy with proton pump inhibitors: a pooled analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Databases, Factual; Endoscopy, Gastrointestinal; Esomeprazo | 2010 |
Maintenance treatment with proton pump inhibitors for reflux esophagitis in pediatric patients: a systematic literature analysis.
Topics: Anti-Ulcer Agents; Child; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Outcome Assessme | 2010 |
Esomeprazole magnesium (Nexium).
Topics: Anti-Ulcer Agents; Esomeprazole; Esophagitis; Gastroesophageal Reflux; Helicobacter Infections; Huma | 2001 |
Esomeprazole: update and clinical review.
Topics: Anti-Ulcer Agents; Clinical Trials as Topic; Drug Labeling; Enzyme Inhibitors; Esomeprazole; Esophag | 2002 |
The impact of gastroesophageal reflux disease on quality of life.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Combined Modality Therapy; Cross-Over St | 2003 |
Sleep issues in gastroesophageal reflux disease: beyond simple heartburn control.
Topics: Antacids; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Omeprazole; Proton Pump Inhibitor | 2003 |
Intravenous lansoprazole: in erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Clinical Trials as | 2004 |
Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastric Aci | 2004 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph | 2004 |
Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.
Topics: Esophagitis; Histamine H2 Antagonists; Humans; Omeprazole; Proton Pump Inhibitors; Randomized Contro | 2005 |
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre | 2006 |
Acid-related disorders and use of antisecretory medication.
Topics: Anti-Ulcer Agents; Denmark; Drug Utilization; Enzyme Inhibitors; Esophagitis; Esophagoscopy; Female; | 2007 |
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastr | 1993 |
The medical management of gastro-oesophageal reflux.
Topics: Anti-Ulcer Agents; Dopamine Antagonists; Esophagitis; Gastroesophageal Reflux; Histamine H2 Antagoni | 1996 |
Lansoprazole: a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Interactions; Esophagitis; Humans; | 1996 |
Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis; Esophagosco | 1997 |
[Alendronate-induced esophagitis. A report of 2 cases].
Topics: Alendronate; Esophagitis; Female; Humans; Middle Aged; Omeprazole; Osteoporosis, Postmenopausal; Suc | 1997 |
Lansoprazole. An update of its pharmacological properties and clinical efficacy in the management of acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastrointestinal Diseases; | 1997 |
Proton-pump inhibitors for gastric acid-related disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Gastric Acid; Helicobacter | 1998 |
Omerprazole and other proton pump inhibitors: pharmacology, efficacy, and safety, with special reference to use in children.
Topics: Barrett Esophagus; Child; Enzyme Inhibitors; Esophagitis; Humans; Lung Diseases; Omeprazole; Peptic | 1998 |
[Indications and use of omeprazole in esophago-gastro-duodenal diseases].
Topics: Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Esophageal Diseases; Esophagitis; Gastritis; | 1999 |
Endoscopy-negative reflux disease.
Topics: Anti-Ulcer Agents; Esophagitis; Esophagoscopy; Female; Gastroesophageal Reflux; Humans; Male; Omepra | 2000 |
Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esophagitis; Humans; Lansoprazole; Omepr | 2001 |
Pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Esoph | 2001 |
Gastroesophageal reflux in infants and children. When to reassure and when to go further.
Topics: Child; Child, Preschool; Enzyme Inhibitors; Esophagitis; Gastroesophageal Reflux; Humans; Infant; Om | 2001 |
Improving opportunities for effective management of gastro-oesophageal reflux disease.
Topics: Anti-Ulcer Agents; Biological Availability; Esomeprazole; Esophagitis; Gastric Mucosa; Gastroesophag | 2001 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
Lansoprazole for maintenance of remission of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Esophagitis; H | 2002 |
Pharmacologic management of gastroesophageal reflux disease.
Topics: Barrett Esophagus; Esomeprazole; Esophagitis; Female; Gastroesophageal Reflux; Humans; Omeprazole; P | 2002 |
Is omeprazole helpful in the management of children with reflux oesophagitis?
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Infant; Male; Omeprazole; Proton Pump Inhibitors | 2002 |
[Intragastric pH modifications induced by antisecretory treatments].
Topics: Duodenal Ulcer; Esophagitis; Gastric Acidity Determination; Gastroesophageal Reflux; Histamine H2 An | 1991 |
[Effects of antisecretory therapy on serum gastrin and argyrophil cells of the fundus mucosa].
Topics: Cimetidine; Duodenal Ulcer; Esophagitis; Gastric Mucosa; Gastrins; Humans; Omeprazole; Ranitidine; V | 1991 |
Therapeutic achlorhydria and risk of gastric cancer.
Topics: Animals; Biomechanical Phenomena; Carcinogens; Esophagitis; Gastric Acid; Humans; Omeprazole; Peptic | 1989 |
49 trials available for omeprazole and Esophagitis
| Article | Year |
|---|---|
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Topics: Abdominal Pain; Anti-Ulcer Agents; Double-Blind Method; Dyspepsia; Esophagitis; Heartburn; Humans; O | 2023 |
Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2020 |
Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Diclofenac; Endoscopy, Gastrointe | 2013 |
Effectiveness of voice therapy in reflux-related voice disorders.
Topics: Adult; Anti-Ulcer Agents; Dysphonia; Esophagitis; Female; Gastroesophageal Reflux; Hoarseness; Human | 2010 |
The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration.
Topics: Adult; Drug Administration Schedule; Esophageal pH Monitoring; Esophagitis; Esophagoscopy; Female; G | 2010 |
Gastroesophageal reflux disease management according to contemporary international guidelines: a translational study.
Topics: Adult; Esophagitis; Female; Gastroesophageal Reflux; Guidelines as Topic; Heartburn; Humans; Male; M | 2011 |
Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aluminum Hydroxide; Anti-Ulcer Agents; Benzimi | 2003 |
Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Dose-Response R | 2002 |
Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Endoscopy, Gast | 2002 |
The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; | 2003 |
On-demand therapy with rabeprazole in nonerosive and erosive gastroesophageal reflux disease in clinical practice: effectiveness, health-related quality of life, and patient satisfaction.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Fema | 2004 |
Prevention of erosive oesophagitis relapse with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Method; Eso | 2004 |
Intravenous and oral lansoprazole are equivalent in suppressing stimulated acid output in patient volunteers with erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Anti-Ulcer A | 2004 |
Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis | 2005 |
Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female | 2006 |
Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis.
Topics: Aged; Anti-Ulcer Agents; Esophagitis; Female; Follow-Up Studies; Fundoplication; Gastroesophageal Re | 2007 |
Comparison of four proton pump inhibitors for the short-term treatment of esophagitis in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Endoscopy, Gast | 2007 |
Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis.
Topics: Aged; Cost-Benefit Analysis; Esophageal Stenosis; Esophagitis; Female; Histamine H2 Antagonists; Hum | 1994 |
Does long-term inhibition of gastric acid secretion with omeprazole lead to small intestinal bacterial overgrowth?
Topics: Adult; Aged; Bacteria; Breath Tests; Esophagitis; Female; Gastric Acid; Humans; Intestine, Small; Ma | 1994 |
Macroscopic healing of esophagitis does not improve esophageal motility.
Topics: Double-Blind Method; Esophagitis; Esophagoscopy; Esophagus; Female; Humans; Male; Manometry; Middle | 1994 |
Omeprazole for the treatment of posterior laryngitis.
Topics: Adult; Aged; Esophagitis; Female; Gastroesophageal Reflux; Humans; Laryngitis; Laryngoscopy; Male; M | 1994 |
Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Duodenal Ulcer; Enterochromaffin Cells; Eso | 1994 |
An open trial of long-term therapy with lansoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug A | 1993 |
Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 1996 |
Efficacy of a pectin-based anti-reflux agent on acid reflux and recurrence of symptoms and oesophagitis in gastro-oesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Antidiarrheals; Cross-Over Studies; Double-Blind Method; Endoscopy, Digesti | 1997 |
Omeprazole is more effective than cimetidine for the relief of all grades of gastro-oesophageal reflux disease-associated heartburn, irrespective of the presence or absence of endoscopic oesophagitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cimetidine; Double-Blind Method; Esophagitis; Female; Ga | 1997 |
Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Enzyme Inhibitors; Esophagitis; Female; Ga | 1997 |
Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Alcohol Drinking; Amoxicillin; Clarithromycin; Drug Therapy | 1996 |
Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.
Topics: Adult; Alginates; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Combinations; D | 1998 |
Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Endoscopy; Esophagitis; Female; Fol | 1998 |
Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; G | 1997 |
Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis.
Topics: Administration, Oral; Anti-Ulcer Agents; Chi-Square Distribution; Cimetidine; Double-Blind Method; E | 1998 |
Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.
Topics: Anti-Ulcer Agents; Double-Blind Method; Drug Administration Schedule; Endoscopy, Gastrointestinal; E | 1998 |
Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
Topics: Adult; Aged; Chromogranin A; Chromogranins; Drug Tolerance; Esophagitis; Female; Gastric Acid; Gastr | 1998 |
Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Double-Blind Method; Esoph | 1998 |
Histological esophagitis: clinical and histological response to omeprazole in children.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis; Esophagoscopy; Female; Gastrins | 1999 |
Omeprazole or ranitidine plus metoclopramide for patients with severe erosive oesophagitis. A cost-effectiveness analysis.
Topics: Anti-Ulcer Agents; Antiemetics; Cost-Benefit Analysis; Double-Blind Method; Drug Combinations; Esoph | 1995 |
On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Denmark; Double-Blind Method; Drug Administration Schedule; Esophagi | 1999 |
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Atrophy; Esophagitis; Female; Gastric Mucosa; Gastrins; | 1999 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Rabeprazole for the prevention of recurrent erosive or ulcerative gastro-oesophageal reflux disease. Rabeprazole Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Analysis of Variance; Benzimidazoles; Dose-Res | 2000 |
Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Child; Child, Preschool; Enzyme Inhibitors; Eso | 2000 |
Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Confidence Intervals; Dose-Res | 2001 |
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
Topics: Adult; Aged; Double-Blind Method; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesopha | 2001 |
Influence of pantoprazole on oesophageal motility, and bile and acid reflux in patients with oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2001 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2001 |
Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the U.S. Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Dose-Response Relationship, Drug; Esophagitis; Esophagosco | 1992 |
High-dose famotidine in the maintenance treatment of refractory esophagitis: results of a "medium-term" open study.
Topics: Adult; Double-Blind Method; Esophagitis; Esophagoscopy; Famotidine; Female; Humans; Male; Middle Age | 1991 |
92 other studies available for omeprazole and Esophagitis
| Article | Year |
|---|---|
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
Black esophagus, is it as bad as it seems?
Topics: Alcoholism; Colonic Pseudo-Obstruction; Esophagitis; Esophagoscopy; Food, Formulated; Gastrointestin | 2019 |
It's What's Up Front That Counts-Part Two: Esophageal Crohn's Disease Complicated by Recurrent Upper Gastrointestinal Bleeding.
Topics: Adalimumab; Anti-Bacterial Agents; Anti-Inflammatory Agents; Budesonide; Colonoscopy; Colostomy; Con | 2019 |
L-arginine-induced esophagitis, report of six cases.
Topics: Adolescent; Arginine; Chest Pain; Child; Deglutition Disorders; Esophageal Mucosa; Esophagitis; Fema | 2020 |
A rare case report of fungal esophagitis combined with giant gastric ulcer in an immunocompetent patient.
Topics: Aged; Anti-Ulcer Agents; Antifungal Agents; Endoscopy, Gastrointestinal; Esophagitis; Fluconazole; H | 2019 |
Successful Treatment of Refractory Lymphocytic Esophagitis With Vedolizumab.
Topics: Adult; Antibodies, Monoclonal, Humanized; Budesonide; Deglutition Disorders; Endoscopy, Digestive Sy | 2019 |
Statin-associated polymyositis following omeprazole treatment.
Topics: Anticholesteremic Agents; Atorvastatin; Drug Interactions; Esophagitis; Gemfibrozil; Heptanoic Acids | 2013 |
Minimal-change esophagitis on narrow-band imaging.
Topics: Endoscopy, Gastrointestinal; Esophagitis; Humans; Male; Middle Aged; Omeprazole | 2008 |
[Upper gastrointestinal bleeding of infrequent cause].
Topics: Acute Disease; Aged, 80 and over; Ampicillin; Anti-Ulcer Agents; Esophagitis; Fatal Outcome; Gastroi | 2008 |
A biodegradable esophageal stent in the treatment of a corrosive esophageal stenosis in a child.
Topics: Absorbable Implants; Burns, Chemical; Caustics; Child; Esophageal Stenosis; Esophagitis; Esophagosco | 2009 |
[Eosinophilic esophagitis: report of three cases].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetates; Adolescent; Child; Cyclopropanes; Eosinophilia; E | 2009 |
Case reports--resolution of Barrett's disease and esophageal epithelial atypia after gastric bypass and LAP-BAND.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Esophagitis; Esophagoscopy; Gastrectomy; Gastric Bypass; Gastr | 2009 |
Editorial: just how "difficult" is it to withdraw PPI treatment?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dyspepsia; Esophagitis; Gastric Acid; Gastroesophageal Refl | 2010 |
De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study.
Topics: Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cl | 2010 |
It is difficult to discontinue PPI treatment in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Dyspepsia; Esophagitis; Gastric A | 2011 |
Long-term maintenance treatment with omeprazole in children with healed erosive oesophagitis: a prospective study.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esophagiti | 2012 |
Severe esophagitis healed in less than a week with intravenous pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Fema | 2003 |
Diagnostic test with omeprazole in patients with posterior laryngitis.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Diet; Endoscopy, Gastrointestinal; Esophagitis; Female; | 2003 |
Helicobacter pylori hiccup.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2003 |
Esophageal Crohn disease in children: a clinical spectrum.
Topics: Child; Child, Preschool; Colonoscopy; Crohn Disease; Endoscopy, Digestive System; Esophagitis; Esoph | 2003 |
Update on prescribing information for pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Clarithromycin; Digoxin; | 2003 |
Omeprazole reduces clozapine plasma concentrations. A case report.
Topics: Adult; Antipsychotic Agents; Clozapine; Cytochrome P-450 CYP1A2; Drug Antagonism; Esophagitis; Femal | 2003 |
[Heartburn without esophagitis. Symptoms more important than the finding?].
Topics: Androstadienes; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ul | 2003 |
Symptomatic and endoscopic outcome of heartburn 3-4.5 years after starting lansoprazole therapy: a prospective study of 142 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Gastrointestinal; Esophagitis; Female; He | 2003 |
Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Child; Cimetidine; Diagnosis, Differential; Enzyme | 2004 |
H pylori infection and reflux oesophagitis.
Topics: Cohort Studies; Drug Therapy, Combination; Esophagitis; Gastroesophageal Reflux; Gastrointestinal Ag | 2004 |
[The best strategies against reflux disease. Acid stomach and the sequelae].
Topics: Anti-Ulcer Agents; Barrett Esophagus; Chest Pain; Esophagitis; Gastroesophageal Reflux; Helicobacter | 2004 |
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Enterochromaffin- | 2005 |
Simultaneous herpetic and candidal esophagitis in an immunocompetent teenager.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acyclovir; Adolescent; Antifungal Agents; Antiviral Agents; | 2005 |
Reversibility of GERD ultrastructural alterations and relief of symptoms after omeprazole treatment.
Topics: Adult; Biopsy; Epithelial Cells; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; Ma | 2005 |
Attenuation of acid induced oesophagitis in VR-1 deficient mice.
Topics: Acute Disease; Animals; Anti-Ulcer Agents; Capsaicin; Endocytosis; Esophagitis; Famotidine; Hydrogen | 2006 |
[Acid inhibitors for asthma patients].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adult; Anti-Ulcer Agents; Asthma; Child; Eosinoph | 2005 |
Proton pump inhibitor failure in gastro-oesophageal reflux disease--what about eosinophilic oesophagitis?
Topics: Adult; Eosinophilia; Esophagitis; Esophagoscopy; Gastroesophageal Reflux; Humans; Male; Omeprazole; | 2006 |
Healing rates for moderate and severe oesophagitis.
Topics: Enzyme Inhibitors; Esophagitis; Humans; Omeprazole; Proton Pump Inhibitors; Treatment Outcome | 2006 |
Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole.
Topics: Adolescent; Anti-Ulcer Agents; Bile Reflux; Child; Child, Preschool; Esophagitis; Female; Gastroesop | 2006 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch | 2006 |
Esophageal intramural pseudodiverticulosis with esophageal strictures successfully treated with dilation therapy.
Topics: Aged; Antifungal Agents; Candidiasis; Catheterization; Chronic Disease; Deglutition Disorders; Diagn | 2006 |
Getting categorical on GERD.
Topics: Anti-Ulcer Agents; Barrett Esophagus; Disease Progression; Esophageal Neoplasms; Esophagitis; Esopha | 2007 |
Long-term proton pump inhibitor use in children: a retrospective review of safety.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Esophagitis; Female; Gastrins; Hum | 2008 |
Duodenogastro-esophageal reflux in children with refractory gastro-esophageal reflux disease.
Topics: Adolescent; Anti-Ulcer Agents; Breath Tests; Child; Duodenum; Endoscopy, Digestive System; Endoscopy | 2007 |
Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Autoantibodies; Duodenal Ulcer; Esophagitis; Female; Humans | 2008 |
[Esophageal Crohn's disease].
Topics: Adrenal Cortex Hormones; Adult; Algorithms; Anti-Ulcer Agents; Crohn Disease; Cyclosporine; Endoscop | 2008 |
Second proton-pump inhibitor marketed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Esophagitis; Humans; Lan | 1995 |
[Stenosing esophagitis in Zollinger-Ellison syndrome].
Topics: Esophageal Stenosis; Esophagectomy; Esophagitis; Gastrectomy; Humans; Male; Middle Aged; Omeprazole; | 1994 |
Treatment of pyrosis does not insure adequate control of gastric acid reflux.
Topics: Barrett Esophagus; Chronic Disease; Esophagitis; Gastroesophageal Reflux; Heartburn; Humans; Hydroge | 1995 |
Long-term treatment of erosive esophagitis with omeprazole: does it work?
Topics: Administration, Oral; Cohort Studies; Drug Administration Schedule; Esophagitis; Follow-Up Studies; | 1995 |
Pharmacokinetics of intravenous omeprazole in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Critical Illness; Esophagitis; Gastric Acidity Determina | 1994 |
24-hour pH monitoring in symptomatic patients without erosive esophagitis who did not respond to antireflux treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Esophagitis; Esophagus; Female; Gastroesophageal | 1994 |
Four-week treatment with omeprazole increases the metabolism of caffeine.
Topics: Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme System; Enzyme Induction; Esophagitis; Fe | 1994 |
Prolonged remission of oesophagitis does not alter the magnitude of oesophageal acid exposure.
Topics: Adult; Aged; Esophagitis; Esophagitis, Peptic; Esophagus; Female; Humans; Hydrogen-Ion Concentration | 1994 |
Comparison of omeprazole and famotidine on esophageal pH in patients with moderate to severe esophagitis: a cross-over study.
Topics: Adult; Aged; Esophagitis; Esophagus; Famotidine; Female; Gastric Acid; Gastroesophageal Reflux; Huma | 1994 |
Esophageal clearance function following treatment of esophagitis.
Topics: Adult; Differential Threshold; Esophagitis; Esophagogastric Junction; Esophagus; Humans; Manometry; | 1994 |
Surgery for uncomplicated gastro-oesophageal reflux.
Topics: Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole | 1993 |
Treatment of refractory ulcerative oesophagitis with omeprazole.
Topics: Esophagitis; Humans; Infant; Male; Omeprazole | 1993 |
[Efficacy and good tolerance of omeprazole in a case of refractory ulcerative esophagitis in the child].
Topics: Child, Preschool; Drug Tolerance; Esophagitis; Humans; Male; Omeprazole; Ulcer | 1993 |
[Gastroesophageal reflux (round table I)].
Topics: Anti-Ulcer Agents; Diagnosis, Differential; Esophagitis; Gastric Acid; Gastroesophageal Reflux; Hist | 1995 |
Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis.
Topics: Adult; Cost-Benefit Analysis; Esophagitis; Fundoplication; Health Care Costs; Humans; Markov Chains; | 1997 |
Video time lapse endoscopy.
Topics: Anti-Ulcer Agents; Endoscopy, Digestive System; Esophagitis; Gastroesophageal Reflux; Humans; Image | 1997 |
Ringed esophagus (feline esophagus) in childhood.
Topics: Adolescent; Anti-Ulcer Agents; Endoscopy; Esophagitis; Esophagus; Humans; Male; Omeprazole; Radiogra | 1997 |
Diffuse alopecia associated with omeprazole.
Topics: Alopecia; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; Female; Gastric Acid; Hair; Humans; Mid | 1997 |
Brush cytology in the diagnosis of neoplasia in Barrett's esophagus.
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Cell Count; Cell Nucleus; Chromatin; C | 1997 |
The use of omeprazole in the pediatric population.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Esophagitis; Female; Humans; Male; Omeprazol | 1998 |
The effect of healing oesophagitis on oesophageal motor function as determined by oesophageal scintigraphy and ambulatory oesophageal motility/pH monitoring.
Topics: Adult; Anti-Ulcer Agents; Esophageal Motility Disorders; Esophagitis; Esophagus; Female; Humans; Hyd | 1998 |
Healing of severe esophagitis improves esophageal peristaltic dysfunction.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophagitis; Esophagus; Humans; Hydrogen-Ion Concentration; Middle A | 1999 |
Effect of CYP2C19 polymorphism on serum levels of vitamin B12 in patients on long-term omeprazole treatment.
Topics: Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C19; Cytochrome P-450 Enzyme | 1999 |
Severe erythrodermic reactions to the proton pump inhibitors omeprazole and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Dermatitis, Exfoliative; Drug Erup | 1999 |
[Diagnostic omeprazole test in suspected reflux-associated chronic cough].
Topics: Adult; Aged; Cough; Diagnosis, Differential; Enzyme Inhibitors; Esophagitis; Female; Gastroesophagea | 1999 |
[Esophagitis complicated with angina pectoris and mediastinitis].
Topics: Angina Pectoris; Antacids; Diagnosis, Differential; Esophagitis; Esophagoscopy; Humans; Male; Medias | 1996 |
Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophagus; Child; Drug Resist | 2000 |
Risk factors for esophageal candidiasis.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Candidiasis; Case-Control Studies | 2000 |
The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis.
Topics: Adult; Aged; Anti-Ulcer Agents; Esophagitis; Female; Gastroesophageal Reflux; Humans; Hydrogen-Ion C | 2000 |
[Analysis of indications and diagnosis of the gastroscopies requested by primary care physicians].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Drug | 2000 |
Should we eradicate Helicobacter pylori in patients with recurrent gastro-oesophageal reflux disease?
Topics: Esophagitis; Gastritis; Gastroesophageal Reflux; Helicobacter Infections; Helicobacter pylori; Human | 2000 |
The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis.
Topics: Antacids; Barrett Esophagus; Cimetidine; Drug Prescriptions; Endoscopy; Esophagitis; Female; Humans; | 2001 |
From the Food and Drug Administration.
Topics: Anti-Ulcer Agents; Diphtheria-Tetanus-acellular Pertussis Vaccines; Epidermolysis Bullosa Dystrophic | 2001 |
High-dose omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia.
Topics: Digestive System Surgical Procedures; Dose-Response Relationship, Drug; Enzyme Inhibitors; Esophagea | 2001 |
Pill-induced esophagitis caused by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophagitis; Female; Humans; Lans | 2001 |
Treatment of erosive oesophagitis with omeprazole: a comparison with different delivery system.
Topics: Anti-Ulcer Agents; Drug Delivery Systems; Esophagitis; Gastroesophageal Reflux; Helicobacter Infecti | 2001 |
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.
Topics: Adult; Cost-Benefit Analysis; Enzyme Inhibitors; Esomeprazole; Esophagitis; Female; Gastroesophageal | 2002 |
High dose Omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia.
Topics: Esophageal Atresia; Esophageal Stenosis; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole | 2002 |
Chickenpox oesophagitis and haematemesis in an immunocompetent adult.
Topics: Acyclovir; Adult; Antiviral Agents; Chickenpox; Esophagitis; Hematemesis; Herpesvirus 3, Human; Huma | 2002 |
[Severe hyponatremia: possible role of omeprazole].
Topics: Aged; Duodenal Ulcer; Esophagitis; Humans; Hyponatremia; Male; Omeprazole; Stomach Diseases | 1992 |
Increased tissue concentrations of the gastrin precursor in patients treated with omeprazole.
Topics: Amino Acid Sequence; Esophagitis; Female; Gastric Mucosa; Gastrins; Humans; Male; Middle Aged; Molec | 1992 |
Oesophageal motor function before and after healing of oesophagitis.
Topics: Adult; Aged; Esophagitis; Esophagus; Female; Humans; Hydrogen-Ion Concentration; Male; Manometry; Mi | 1992 |
Sexual disturbances during omeprazole therapy.
Topics: Aged; Esophagitis; Humans; Male; Omeprazole; Priapism | 1991 |
Omeprazole.
Topics: Duodenal Ulcer; Esophagitis; Gastroesophageal Reflux; Humans; Omeprazole; Stomach Ulcer | 1991 |
[Omeprazole: crucial progress in the treatment of esophagitis in progressive systemic scleroderma].
Topics: Esophagitis; Female; Humans; Middle Aged; Omeprazole; Scleroderma, Systemic | 1991 |
Omeprazole in the treatment of erosive oesophagitis refractory to high dose cimetidine and ranitidine.
Topics: Adult; Aged; Aged, 80 and over; Cimetidine; Esophagitis; Female; Humans; Male; Middle Aged; Omeprazo | 1990 |
[Advances in the knowledge of peptic-acid dependent diseases].
Topics: Congresses as Topic; Esophagitis; Gastric Acid; Humans; Omeprazole; Peptic Ulcer | 1989 |
Treatment of oesophagitis in scleroderma with omeprazole.
Topics: Esophagitis; Humans; Omeprazole; Pilot Projects; Scleroderma, Systemic | 1989 |
Long term management of hemorrhagic esophagitis with cimetidine and omeprazole.
Topics: Anemia; Anti-Ulcer Agents; Benzimidazoles; Cimetidine; Esophagitis; Gastrointestinal Hemorrhage; Hum | 1986 |